GlobeImmune

GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases.[1] As of August 2014, the company had no marketed products.[2] GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.

The company has partnerships with Celgene (established in 2009)[1] and the National Cancer Institute for the development of cancer vaccines.[3][4] Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.[5]

With respect to financing in the absence of revenue, the company raised US$17.5 million through a Series E Preferred Stock offering in January 2010.[1]

As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers.[6] Completed trials have addressed two other candidates, GI-4000 (the company's lead oncology candidate as of 2010)[1] and GI-5005.[6] Despite there being three ongoing trials, in July 2015 the company announced it would eliminate "most of its workforce positions" shortly following the failure of a trial examining GI-4774.[7]

In March 2017, GlobeImmune announced that it has entered into a definitive purchase agreement for the sale of shares of its common stock to NantCell, Inc.[8]

External links

• GlobeImmune website